Table 1.

Utilization of Xtampza ER and Comparator Oxycodone Groups Within the ASI-MV Network

Group	Description	Prescriptions Dispensed	% of All Opioids Dispensed	% of All Oxycodone Dispensed	% of All Oxycodone ER Dispensed
Xtampza ER	Xtampza ER (entered market in Q3 2016; added to ASI-MV Q3 2017)	831,552	0.1	0.5	7.8
Other oxycodone ER*	Other oxycodone ER products excluding Xtampza ER (solid oral dosage forms)	9,891,591	1.5	6.1	92.2
Oxycodone IR	Oxycodone IR products (solid oral dosage forms), including single-entity and combination products	150,629,158	23.0	93.4	N/A

Note: *During the study period, the prescriptions dispensed within the other oxycodone ER product grouping were almost solely comprised of OxyContin and authorized generics (>99%).

Abbreviations: ER, extended-release; IR, immediate-release; ASI-MV, Addiction Severity Index-Multimedia Version.